Peptides by condition · Weight, blood sugar, liver and gut
Peptides studied for obesity
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 71 study pages on obesity: 63 in people (55 of them meta-analyses or randomized trials), and 8 in animals. They studied 23 compounds, with this many study pages each: Semaglutide 12, Tirzepatide 11, Setmelanotide 8, Retatrutide 7, Liraglutide 3, Cagrilintide 3, Survodutide 3, Orforglipron 2, CagriSema 2, Mazdutide 2, Pramlintide 2, Amycretin 3, Ecnoglutide 1, Efinopegdutide 1, Exenatide 1, Eloralintide 1, Enicepatide 1, Petrelintide 1, VK2735 1, AOD-9604 3, 5-Amino-1MQ 1, MOTS-c 1 and SLU-PP-332 1.
What the research on obesity looks like
Obesity is a long-term disease in which extra body fat raises the risk of diabetes, heart disease, joint pain and more. It is the condition with by far the most peptide research in people: the drugs that copy gut hormones such as GLP-1 have been tested in large trials lasting a year or longer, and several are now prescription medicines.
Obesity trials mostly measure the share of body weight lost against a placebo group, and how many people reach a set amount of loss. Some also scan the body to split the loss into fat and lean mass, or follow blood fats, blood pressure and heart events.
When reading these studies, look at how long the trial ran, whether the comparison was a placebo or another drug, and what happened after people stopped. A result in obese mice is a first step and says little about a person.

Model. Individual results vary.
The 71 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Semaglutide
12 in peopleFor obesity, 12 of our study pages are filed under Semaglutide: 1 meta-analysis and 11 randomized trials in people. The largest in people enrolled 17,604 people and was published in 2024. They were published from 2021 to 2025, in J ASEAN Fed Endocr Soc, Nat Med, N Engl J Med, Lancet Diabetes Endocrinol, Lancet, JAMA, NEJM Evid and Diabetes Obes Metab.
FDA-approved, with a use tied to obesity on its label: Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight. Under Ozempic and Rybelsus it is approved for other uses.
- Meta-analysis in people · 3,613 people · 2022Semaglutide: 11.85% more weight loss than placebo without diabetes
- Randomized trial in people · 17,604 people · 2024Semaglutide: 10.2% weight loss at 208 weeks in SELECT
- Randomized trial in people · 17,604 people · 2023Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT
- Randomized trial in people · 1,961 people · 2021Semaglutide: 14.9% weight loss at 68 weeks in STEP 1
- Randomized trial in people · 1,407 people · 2025Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UP
- Randomized trial in people · 1,210 people · 2021Semaglutide 2.4 mg: 9.6% weight loss at 68 weeks in STEP 2
- Randomized trial in people · 803 people · 2021Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placebo
- Randomized trial in people · 667 people · 2023Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1
- Randomized trial in people · 611 people · 2021Semaglutide: 16.0% weight loss at 68 weeks with therapy in STEP 3
- Randomized trial in people · 72 people · 2025Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetes
- Randomized trial in people · 72 people · 2021Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeks
- Randomized trial in people · 2025Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4
Tirzepatide
11 in peopleFor obesity, 11 of our study pages are filed under Tirzepatide: 11 randomized trials in people. The largest in people enrolled 2,539 people and was published in 2022. They were published from 2022 to 2026, in N Engl J Med, Clin Obes, Lancet, JAMA, Diabetes Obes Metab, Nat Med and Sleep Med.
FDA-approved, with a use tied to obesity on its label: Zepbound (injection) for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity. Under Mounjaro it is approved for other uses.
- Randomized trial in people · 2,539 people · 2022Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1
- Randomized trial in people · 1,438 people · 2025Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1
- Randomized trial in people · 1,032 people · 2025Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1
- Randomized trial in people · 938 people · 2023Tirzepatide 15 mg: 14.7% weight loss at 72 weeks in SURMOUNT-2
- Randomized trial in people · 751 people · 2025Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeks
- Randomized trial in people · 378 people · 2026Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks
- Randomized trial in people · 210 people · 2024Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CN
- Randomized trial in people · 160 people · 2025Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1
- Randomized trial in people · 102 people · 2026Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE
- Randomized trial in people · 2025Tirzepatide: better sleep and quality of life scores in SURMOUNT-OSA
- Randomized trial in people · 2024Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSA
Setmelanotide
8 in peopleFor obesity, 8 of our study pages are filed under Setmelanotide: 1 meta-analysis, 1 randomized trial and 6 clinical trials in people. The largest in people pooled 185 people and was published in 2026. They were published from 2017 to 2026, in Expert Opin Drug Saf, N Engl J Med, Front Behav Neurosci, Lancet Diabetes Endocrinol, Orphanet J Rare Dis and Mol Metab.
FDA-approved, with a use tied to obesity on its label: Imcivree (injection) for reducing excess weight and keeping it off in rare kinds of obesity: acquired hypothalamic obesity (age 4 and older), and Bardet-Biedl syndrome or a confirmed POMC, PCSK1 or LEPR gene deficiency (age 2 and older).
- Meta-analysis in people · 185 people · 2026Setmelanotide: injection-site reactions in 96% in pooled trials
- Randomized trial in people · 120 people · 2026Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesity
- Clinical trial in people · 30 people · 2026Setmelanotide: patients reported less hunger, more energy in TRANSCEND
- Clinical trial in people · 18 people · 2024Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesity
- Clinical trial in people · 12 people · 2025Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)
- Clinical trial in people · 2023Setmelanotide: quality of life rose after 52 weeks in Bardet-Biedl
- Clinical trial in people · 2020Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weight
- Clinical trial in people · 2017Setmelanotide: people with MC4R gene changes lost weight in 28 days
Retatrutide
6 in people · 1 in animalsFor obesity, 7 of our study pages are filed under Retatrutide: 1 meta-analysis, 3 randomized trials and 2 clinical trials in people, and 1 animal study (mice). The largest in people pooled 29,506 people and was published in 2025. They were published from 2023 to 2026, in Obesity (Silver Spring), N Engl J Med, Diabetes Obes Metab, Kidney Int Rep and Int J Obes (Lond).
Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.
- Meta-analysis in people · 29,506 people · 2025Retatrutide: top odds of 15% or more weight loss across 19 trials
- Randomized trial in people · 2,339 people · 2026Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1
- Randomized trial in people · 338 people · 2023Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg arm
- Randomized trial in people · 2026Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials
- Clinical trial in people · 2025Retatrutide 12 mg: UACR 37.0% lower vs placebo in type 2 diabetes
- Clinical trial in people · 2025Retatrutide lowered ANGPTL3/8 in step with triglycerides and LDL-C
- Animal study in mice · 2026Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 days
Liraglutide
3 in peopleFor obesity, 3 of our study pages are filed under Liraglutide: 3 randomized trials in people. The largest in people enrolled 3,731 people and was published in 2015. They were published from 2015 to 2022, in N Engl J Med and JAMA.
FDA-approved, with a use tied to obesity on its label: Saxenda (injection) for weight loss and keeping it off, in adults and in children 12 and older with obesity. Under Victoza it is approved for other uses.
- Randomized trial in people · 3,731 people · 2015Liraglutide: 8.4 kg lost vs 2.8 kg on placebo at 56 weeks
- Randomized trial in people · 338 people · 2022Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8
- Randomized trial in people · 195 people · 2021Liraglutide plus exercise: 9.5 kg more loss than placebo at 1 year
Cagrilintide
3 in peopleFor obesity, 3 of our study pages are filed under Cagrilintide: 3 randomized trials in people. The largest in people enrolled 3,417 people and was published in 2025. They were published from 2021 to 2026, in N Engl J Med, Lancet and Diabetes Obes Metab.
Cagrilintide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.
- Randomized trial in people · 3,417 people · 2025Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1
- Randomized trial in people · 96 people · 2021Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20
- Randomized trial in people · 2026CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeks
Survodutide
3 in peopleFor obesity, 3 of our study pages are filed under Survodutide: 3 randomized trials in people. The largest in people enrolled 725 people and was published in 2026. They were published from 2024 to 2026, in N Engl J Med, Lancet Diabetes Endocrinol and Nat Med.
Survodutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing survodutide, among others, labeled “for research purposes”.
- Randomized trial in people · 725 people · 2026Survodutide: up to 13.0% weight loss at 76 weeks in SYNCHRONIZE-1
- Randomized trial in people · 387 people · 2024Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trial
- Randomized trial in people · 216 people · 2026Survodutide: 12.2% weight loss and less liver fat at 48 weeks
Orforglipron
2 in peopleFor obesity, 2 of our study pages are filed under Orforglipron: 2 randomized trials in people. The largest in people enrolled 3,127 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and Lancet.
FDA-approved, with a use tied to obesity on its label: Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition.
- Randomized trial in people · 3,127 people · 2025Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1
- Randomized trial in people · 1,613 people · 2026Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2
CagriSema
2 in peopleFor obesity, 2 of our study pages are filed under CagriSema: 2 randomized trials in people. The largest in people enrolled 1,206 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and Lancet Diabetes Endocrinol.
CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy).
- Randomized trial in people · 1,206 people · 2025CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2
- Randomized trial in people · 331 people · 2026CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5
Mazdutide
2 in peopleFor obesity, 2 of our study pages are filed under Mazdutide: 2 randomized trials in people. The largest in people enrolled 610 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and JAMA.
Mazdutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing mazdutide, among others, labeled “for research purposes”.
- Randomized trial in people · 610 people · 2025Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)
- Randomized trial in people · 461 people · 2026Mazdutide: 16.65% average weight loss at 60 weeks in GLORY-2
Pramlintide
2 in peopleFor obesity, 2 of our study pages are filed under Pramlintide: 2 randomized trials in people. The largest in people enrolled 411 people and was published in 2008. They were published from 2007 to 2008, in Diabetes Care and J Clin Endocrinol Metab.
FDA-approved for other uses, not for obesity: Symlin for adding to mealtime insulin in type 1 or type 2 diabetes when insulin alone has not reached the blood sugar goal.
- Randomized trial in people · 411 people · 2008Pramlintide: weight loss maintained over 12 months in obesity
- Randomized trial in people · 204 people · 2007Pramlintide: 3.7% placebo-corrected weight loss at 16 weeks
Amycretin
2 in people · 1 in animalsFor obesity, 3 of our study pages are filed under Amycretin: 2 randomized trials in people, and 1 animal study (mice and rats). The largest in people enrolled 144 people and was published in 2025. All were published in 2025, in Lancet and EBioMedicine.
Amycretin has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 144 people · 2025Amycretin: side effects all mild or moderate in first human trial
- Randomized trial in people · 125 people · 2025Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trial
- Animal study in mice and rats · 2025Amycretin cut body weight by 18% in obese rats over 21 days
Ecnoglutide
1 in peopleFor obesity, 1 of our study pages is filed under Ecnoglutide: 1 randomized trial in people. It enrolled 664 people and was published in 2025, in Lancet Diabetes Endocrinol.
Ecnoglutide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 664 people · 2025Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg arm
Efinopegdutide
1 in peopleFor obesity, 1 of our study pages is filed under Efinopegdutide: 1 randomized trial in people. It enrolled 195 people and was published in 2021, in Clin Obes.
Efinopegdutide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 195 people · 2021Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeks
Exenatide
1 in peopleFor obesity, 1 of our study pages is filed under Exenatide: 1 randomized trial in people. It enrolled 119 people and was published in 2021, in J Clin Endocrinol Metab.
FDA-approved for other uses, not for obesity: Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.
- Randomized trial in people · 119 people · 2021Exenatide, alone or with dapagliflozin, improved blood sugar in PCOS
Eloralintide
1 in peopleFor obesity, 1 of our study pages is filed under Eloralintide: 1 randomized trial in people. It enrolled 100 people and was published in 2026, in Diabetes Obes Metab.
Eloralintide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 100 people · 2026Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1
Enicepatide
1 in peopleFor obesity, 1 of our study pages is filed under Enicepatide: 1 randomized trial in people. It was published in 2026, in Mol Metab, and our page does not give its size.
Enicepatide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 2026Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1
Petrelintide
1 in peopleFor obesity, 1 of our study pages is filed under Petrelintide: 1 randomized trial in people. It was published in 2026, in Diabetes Obes Metab, and our page does not give its size.
Petrelintide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 2026Petrelintide: up to 8.6% weight loss at 16 weeks in phase 1
VK2735
1 in peopleFor obesity, 1 of our study pages is filed under VK2735: 1 randomized trial in people. It was published in 2026, in Obesity (Silver Spring), and our page does not give its size.
VK2735 has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 2026VK2735: up to 14.7% weight loss at 13 weeks in VENTURE
AOD-9604
3 in animalsFor obesity, 3 of our study pages are filed under AOD-9604: 3 animal studies (mice and obese Zucker rats). None of them is in people. They were published from 1994 to 2001, in Endocrinology, Horm Res and Biochem Mol Biol Int.
AOD-9604 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2001AOD-9604 lowered body weight and body fat in obese mice over 14 days
- Animal study in obese Zucker rats · 2000AOD-9604 cut weight gain by over 50% in obese Zucker rats
- Animal study in mice · 1994AOD-9604 reduced weight gain and fat tissue mass in obese mice
5-Amino-1MQ
1 in animalsFor obesity, 1 of our study pages is filed under 5-Amino-1MQ: 1 animal study (mice). It was published in 2022, in Sci Rep.
5-amino-1MQ has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 20225-Amino-1MQ plus low-fat diet gave obese mice a distinct microbiome
MOTS-c
1 in animalsFor obesity, 1 of our study pages is filed under MOTS-c: 1 animal study (mice). It was published in 2015, in Cell Metab.
MOTS-c has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2015MOTS-c prevented diet-induced obesity and insulin resistance in mice
SLU-PP-332
1 in animalsFor obesity, 1 of our study pages is filed under SLU-PP-332: 1 animal study (mice). It was published in 2024, in J Pharmacol Exp Ther.
SLU-PP-332 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2024SLU-PP-332 cut fat mass and improved insulin sensitivity in obese mice
Side by side
For the 23 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Semaglutide | 12 | 0 | 17,604 | Approved, a use tied to it |
| Tirzepatide | 11 | 0 | 2,539 | Approved, a use tied to it |
| Setmelanotide | 8 | 0 | 185 | Approved, a use tied to it |
| Retatrutide | 6 | 1 | 29,506 | Not approved |
| Liraglutide | 3 | 0 | 3,731 | Approved, a use tied to it |
| Cagrilintide | 3 | 0 | 3,417 | Not approved |
| Survodutide | 3 | 0 | 725 | Not approved |
| Orforglipron | 2 | 0 | 3,127 | Approved, a use tied to it |
| CagriSema | 2 | 0 | 1,206 | Not approved |
| Mazdutide | 2 | 0 | 610 | Not approved |
| Pramlintide | 2 | 0 | 411 | Approved for other uses |
| Amycretin | 2 | 1 | 144 | Not approved |
| Ecnoglutide | 1 | 0 | 664 | Not approved |
| Efinopegdutide | 1 | 0 | 195 | Not approved |
| Exenatide | 1 | 0 | 119 | Approved for other uses |
| Eloralintide | 1 | 0 | 100 | Not approved |
| Enicepatide | 1 | 0 | — | Not approved |
| Petrelintide | 1 | 0 | — | Not approved |
| VK2735 | 1 | 0 | — | Not approved |
| AOD-9604 | 0 | 3 | — | Not approved |
| 5-Amino-1MQ | 0 | 1 | — | Not approved |
| MOTS-c | 0 | 1 | — | Not approved |
| SLU-PP-332 | 0 | 1 | — | Not approved |
- In people
- 12
- Animals or cells
- 0
- Largest in people
- 17,604
- FDA
- Approved, a use tied to it
- In people
- 11
- Animals or cells
- 0
- Largest in people
- 2,539
- FDA
- Approved, a use tied to it
- In people
- 8
- Animals or cells
- 0
- Largest in people
- 185
- FDA
- Approved, a use tied to it
- In people
- 6
- Animals or cells
- 1
- Largest in people
- 29,506
- FDA
- Not approved
- In people
- 3
- Animals or cells
- 0
- Largest in people
- 3,731
- FDA
- Approved, a use tied to it
- In people
- 3
- Animals or cells
- 0
- Largest in people
- 3,417
- FDA
- Not approved
- In people
- 3
- Animals or cells
- 0
- Largest in people
- 725
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 3,127
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 1,206
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 610
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 411
- FDA
- Approved for other uses
- In people
- 2
- Animals or cells
- 1
- Largest in people
- 144
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 664
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 195
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 119
- FDA
- Approved for other uses
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 100
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- —
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- —
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 3
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Semaglutide: 11.85% more weight loss than placebo without diabetesThe analysis rests on only 4 trials and covers only semaglutide given as a shot under the skin. It doesn't apply to people with type 2 diabetes, who were not included.
- Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1People with diabetes were excluded, and the trial ran for 72 weeks, so it does not show longer-term results or results in people with diabetes. The study was funded by Eli Lilly.
- Setmelanotide: injection-site reactions in 96% in pooled trialsThe pooled rates show how often each side effect happened in people taking setmelanotide, not how much more often than without it, and they rest on only 185 people. Reports sent to a safety database flag possible signals but cannot show how common an effect is.
- Retatrutide: top odds of 15% or more weight loss across 19 trialsThis study pooled 19 earlier trials rather than running a new one, and it grouped GLP-1 drugs and dual agonists into classes. It covers only adults with a BMI of 25 kg/m2 or more, with outcomes at 36 weeks or later.
- Liraglutide: 8.4 kg lost vs 2.8 kg on placebo at 56 weeksThe trial ran 56 weeks, so it does not show what happens over longer use or after stopping, and it excluded people with type 2 diabetes. Most patients were women (78.5%), and Novo Nordisk funded the study.
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1The main comparisons were made against placebo, not against either drug alone, and the trial only enrolled adults without diabetes over 68 weeks. It was funded by Novo Nordisk.
- Survodutide: 12.2% weight loss and less liver fat at 48 weeksThe trial lasted only 48 weeks and enrolled people only in the United States and Spain. It tested a single dose, 6.0 mg, against placebo.
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1The trial included only adults with obesity who did not have diabetes, and it compared orforglipron with placebo, not with other weight-loss medicines. It was funded by Eli Lilly.
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2The trial compared CagriSema only with placebo, so it doesn't show how the pair does against either drug alone, and it ran for 68 weeks in people with type 2 diabetes. It was funded by Novo Nordisk.
- Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)The trial included only Chinese adults and ran for 48 weeks, so it does not show longer-term effects or results in other populations. It was funded by Innovent Biologics.
- Pramlintide: weight loss maintained over 12 months in obesityOnly 146 people could be evaluated at month 12, and the extension was single-blind and open to those who chose to continue, so the 12-month results come from a smaller, self-selected group. Every participant also followed a structured lifestyle program, so the results apply to pramlintide used together with one.
- Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg armThe trial included only Chinese adults without diabetes and ran for 40 weeks, so it does not show longer-term results or results in other groups. It was funded by Hangzhou Sciwind Biosciences.
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSThe trial ran 24 weeks and had no placebo arm, so every group got an active drug. It included only women without diabetes who had obesity and PCOS, so it doesn't show how these drugs work in other groups.
- Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1This was an early, short trial of about 4 weeks in otherwise healthy people, so it can't show longer-term weight loss or how the drug works in people with type 2 diabetes. The liver and appetite results came from mice, not people.
- Petrelintide: up to 8.6% weight loss at 16 weeks in phase 1These were early phase 1 trials built mainly to test safety and dosing, and the longest dosing lasted only 16 weeks. They don't show how petrelintide performs over longer periods or in larger groups of people with obesity.
- VK2735: up to 14.7% weight loss at 13 weeks in VENTUREAt 13 weeks, this trial is short and does not show what happens with longer use or after stopping. People with diabetes were not included, and the placebo group was small.
- AOD-9604 cut weight gain by over 50% in obese Zucker ratsThis was a short 19-day study in one strain of obese rats at a single dose, so it is not a result in people. It measured slower weight gain, not weight loss.
- SLU-PP-332 cut fat mass and improved insulin sensitivity in obese miceThis was done only in mice, so it does not show the same effects in people. It tested obese mouse models and did not compare the compound with actual exercise in a human trial.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for obesity?
Our 71 study pages on obesity are filed under 23 compounds, with this many each: Semaglutide 12, Tirzepatide 11, Setmelanotide 8, Retatrutide 7, Liraglutide 3, Cagrilintide 3, Survodutide 3, Orforglipron 2, CagriSema 2, Mazdutide 2, Pramlintide 2, Amycretin 3, Ecnoglutide 1, Efinopegdutide 1, Exenatide 1, Eloralintide 1, Enicepatide 1, Petrelintide 1, VK2735 1, AOD-9604 3, 5-Amino-1MQ 1, MOTS-c 1 and SLU-PP-332 1. Semaglutide has the most.
Have any been tested in people with obesity?
Yes: 63 of the 71 were in people, 55 of them meta-analyses or randomized trials (Semaglutide, Tirzepatide, Setmelanotide, Retatrutide, Liraglutide, Cagrilintide, Survodutide, Orforglipron, CagriSema, Mazdutide, Pramlintide, Amycretin, Ecnoglutide, Efinopegdutide, Exenatide, Eloralintide, Enicepatide, Petrelintide and VK2735). The largest pooled 29,506 people: “Retatrutide: top odds of 15% or more weight loss across 19 trials” (2025).
Is any peptide FDA-approved for obesity?
Yes, with a use tied to obesity on their FDA labels: Semaglutide as Wegovy; Tirzepatide as Zepbound; Setmelanotide as Imcivree; Liraglutide as Saxenda; Orforglipron as Foundayo. 18 other compounds here with an FDA record have no use tied to it.
How large were the studies in people on obesity?
Of the 63 in people, 50 give their size on our pages: 16 had 1,000 people or more, 28 had 100 to 999 and 6 had fewer than 100. The largest, a meta-analysis from 2025, pooled 29,506.
What did the animal and cell studies on obesity use?
8 animal studies (mice, rats and obese Zucker rats), filed under Retatrutide, Amycretin, SLU-PP-332, 5-Amino-1MQ, MOTS-c and AOD-9604. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on obesity here?
Of our study pages on obesity, the newest is “Setmelanotide: injection-site reactions in 96% in pooled trials”, a meta-analysis in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.